e-learning
resources
London 2016
Wednesday, 07.09.2016
Airway pharmacology: drug targets and mode of action
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10
Robert Newton (Calgary, AB, Canada), Suharsh Shah, Mahmoud Mostafa, Mohammed Altonsy, Robert Newton
Source:
International Congress 2016 – Airway pharmacology: drug targets and mode of action
Session:
Airway pharmacology: drug targets and mode of action
Session type:
Poster Discussion
Number:
5068
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Robert Newton (Calgary, AB, Canada), Suharsh Shah, Mahmoud Mostafa, Mohammed Altonsy, Robert Newton. Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10. Eur Respir J 2016; 48: Suppl. 60, 5068
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Incorrect inhaler technique is common in patients with COPD – Data from the TIE study
A prospective study of the effect of carbocysteine lysine salt on COPD exacerbations with or without inhaled steroids
The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases
Related content which might interest you:
Inhibition of inflammatory gene expression by dexamethasone partly depends on the phosphatase, MKP-1 (DUSP1)
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013
Importin-7 knockdown reduces corticosteroid induced glucocorticoid receptor nuclear localisation and suppression of IL-1beta induced CXCL8
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Decreased PTEN amplifies PI3K signaling and enhances pro-inflammatory cytokine release in COPD
Source: International Congress 2016 – Studies in airway cell biology
Year: 2016
Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cAMP in human macrophages
Source: International Congress 2015 – Mucosal immunology: what’s new in 2015
Year: 2015
Cytokine-induced glucocorticoid resistance: Effect on GILZ expression and reversal by formoterol
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013
Egr-1 regulates muc5ac expression through activator protein-1 (AP-1) in chronic airway inflammation diseases
Source: International Congress 2015 – Translational studies in airway cell biology
Year: 2015
Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma
Source: Eur Respir J 2010; 35: 750-756
Year: 2010
Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
Glucocorticoids promote TGF-β signalling in lung fibroblasts by upregulating ligand and receptor expression, and uncoupling negative-feedback inhibition
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Dexamethasone inhibits LPS-induced expression of human β-defensin-2 via down-regulation of TLR4
Source: Eur Respir J 2003; 22: Suppl. 45, 562s
Year: 2003
Decoy chemokine neutraligands with anti-asthmatic activity
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
WNT-4 regulates pro-inflammatory responses driven by epithelial-mesenchymal cross-talk
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
Alpha-1-antitrypsin regulates IL-8 release and CXCR2 expression in human neutrophils
Source: International Congress 2014 – Cells, biofilms and biomarkers in respiratory infections
Year: 2014
cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
Corticosteroids reduce pro-inflammatory cytokine expression in airway smooth muscle cells via upregulation of MAPK phosphatase-1 and inhibition of p38 MAPK signalling
Source: Eur Respir J 2005; 26: Suppl. 49, 713s
Year: 2005
Endothelin-1 activates pro-inflammatory signalling pathway via destinct p38MAPK isoforms resulting in downregulation of nuclear p27
kip1
Source: Annual Congress 2009 - Airway cell biology
Year: 2009
Nrf2-dependent and -independent cytoprotective actions of the electrophilic Cox-2-derived 17-oxo-DHA in human macrophages
Source: International Congress 2014 – New insights into monocyte and macrophage biology
Year: 2014
Resveratrol upregalates PTEN and inhibits MUC5AC expression in ovalbumin (OVA)-induced asthma model mice
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept